Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …

Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …

Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

Gastric cancer (GC) is one of the most common malignancies worldwide and it is the fourth
leading cause of cancer-related death. GC is a multifactorial disease, where both …

Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …